产品名称
1.1E7, from human pancreas(islets), 10070101
biological source
human pancreas (islets)
growth mode
Adherent
karyotype
Modal chromosome number 67-71
morphology
Epitheloid
products
1.1E7 cells have been shown to express insulin, glucokinase and IAPP by immunocytochemistry
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
shipped in
dry ice
Biochem/physiol Actions
1.1E7 is a hybrid cell line formed by the electrofusion of a primary culture of human pancreatic islets with PANC-1, a human pancreatic ductal carcinoma cell line (ECACC catalogue number 87092802). 1.1E7 has been shown to be tumourigenic when transplanted into a SCID mouse host. The cell line has applications in the study of pancreatic cell biology. 1.1E7 cells provide a method of producing pure insulin secreting cells when stimulated . This is an alternative to the use of primary tissue in cell transplantation therapies for type 1 diabetes. The Y chromosome could not be detected in this cell line by short tandem repeat (STR)-PCR analysis when tested at ECACC. It is a known phenomenon that due to the increased genetic instability of cancer cell lines the Y chromosome can be rearranged or lost resulting in lack of detection. The cell line is identical to the source provided by the depositor based on the STR-PCR analysis.
STR-PCR Data:
Amelogenin: X
CSF1PO: 10,12
D13S317: 11
D16S539: 11
D5S818: 11,13
D7S820: 8
THO1: 7,8
TPOX: 8,11
vWA: 15
Amelogenin: X
CSF1PO: 10,12
D13S317: 11
D16S539: 11
D5S818: 11,13
D7S820: 8
THO1: 7,8
TPOX: 8,11
vWA: 15
Preparation Note
RPMI-1640 + 2 mM Glutamine + 10% FCS / FBS
Split sub-confluent cultures (70-80%) 1:2 to 1:6 , i.e., seeding at 2-4 x 104 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37 °C. Population doubling approx 23hrs. At confluence 105 cells/cm2 can be expected.
Other Notes
Cultures from HPA Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Legal Information
Flatt P & McClenaghan N (2004) Insulin producing cell-line US patent number 20040005702 (A1). Also WO0210346 (A2).